Serica

Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

Retrieved on: 
Thursday, March 10, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 8:00 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 8:00 a.m.
  • An audio webcast of the presentation will be available under the Investors and News section of Seres website.
  • A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

Retrieved on: 
Thursday, March 3, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m.
  • An audio webcast of the panel discussion will be available under the Investors and Media section of Seres website.
  • A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022

Retrieved on: 
Tuesday, February 22, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m.
  • ET to discuss fourth quarter and full year 2021 results and provide a general business update.
  • To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6277858.
  • To join the live webcast, please visit the Investors and Media section of the Seres website at www.serestherapeutics.com .

Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit

Retrieved on: 
Tuesday, February 22, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 2:00 p.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 2:00 p.m.
  • An audio webcast of the presentation will be available under the Investors and Media section of Seres website.
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.
  • Seres SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Retrieved on: 
Tuesday, February 8, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive Vice President, Chief People Officer effective February 7, 2022, reporting directly to Eric Shaff, President and Chief Executive Officer.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive Vice President, Chief People Officer effective February 7, 2022, reporting directly to Eric Shaff, President and Chief Executive Officer.
  • Paula joins the Seres leadership team at a pivotal time of growth.
  • She most recently served as Chief People Officer at Translate Bio, Inc., where she led the talent architecture and people strategy.
  • Im excited for the opportunity to help oversee and support the continued growth of the top-flight Seres team, Cloghessy said.

Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022

Retrieved on: 
Monday, January 24, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2022, from 8:30 a.m. to 10:00 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2022, from 8:30 a.m. to 10:00 a.m.
  • The event will focus on the development of microbiome therapeutics as a novel approach for infection protection in medically compromised individuals.
  • Seres is also evaluating additional preclinical stage programs targeting infection protection in medically compromised patients.
  • Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection

Retrieved on: 
Wednesday, January 19, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI).
  • The SER-109 ECOSPOR III Phase 3 study ( ClinicalTrials.gov identifier: NCT03183128) was a multicenter, randomized, placebo-controlled study.
  • In May 2021, Seres presented 24-week clinical data from the study that demonstrated significantly reduced recurrence rates compared to placebo.
  • The SER-109 program is being advanced to reduce the recurrence of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.

Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 4, 2022

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:15 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:15 a.m.
  • A live audio webcast of the presentation will be available under the Investors and News section of Seres website.
  • A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.
  • Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

Retrieved on: 
Thursday, December 16, 2021

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).
  • Following the topline clinical data readout in July, which noted that the SER-287 Phase 2b study did not achieve its primary endpoints, analysis of the microbiome data demonstrated the successful engraftment of SER-287 bacterial species.
  • However, unlike the Phase 1b study, anticipated changes in disease-relevant metabolites post-administration with SER-287 in the Phase 2b study were not observed.
  • We continue to evaluate SER-287 study data, while also examining preliminary SER-301 Phase 1b study clinical and microbiome data, including analysis of changes in disease-relevant metabolites.

Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021

Retrieved on: 
Thursday, July 29, 2021

Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m.
  • ET to discuss second quarter 2021 results and provide a general business update.
  • To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6519859.
  • To join the live webcast, please visit the Investors and Media section of the Seres website at www.serestherapeutics.com .